Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review)

被引：0
作者：
Boyko, A. N. [1 ]
Gusev, E. I.
机构：
[1] Pirogov Russian Natl Res Med Univ, Moscow, Russia
来源：
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA | 2013年 / 113卷 / 02期
关键词：
multiple sclerosis; therapy; neuroprotection; laquinimod; SECONDARY PROGRESSIVE MS; KAPPA-B; LINOMIDE; ABR-215062; TRIAL;
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
New oral therapies of MS cause great attention. This review includes data on the II and III phase clinical studies of laquinimod (LAQ) - a new oral therapy for MS with immunoregulatory, anti inflammatory and neuroprotective action. LAQ has no immunosupressive effects and has a very good safety and tolerability profile. Data of phase III studies including 2437 MS patients confirmed positive effect of LAQ on relapse rate and disability progression. These clinical results were supported by the MRI data, showing also a significant slowing of the brain atrophy. Russian neurological clinics actively participated in all LAQ clinical trials: 241 MS patients from 11 centers from Russia took part in the phase II trials. The data in this subgroup confirm all changes, registered in the whole group of patients.
引用
收藏
页码：93 / 99
页数：7
相关论文
共 50 条
  • [31] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    Annibali, V.
    Ristori, G.
    Cannoni, S.
    Romano, S.
    Visconti, A.
    Ghazaryan, A.
    Talamanca, L. Figa
    Salvetti, M.
    Mechelli, R.
    NEUROLOGICAL SCIENCES, 2006, 27 (Suppl 5) : S347 - S349
  • [32] Multiple sclerosis: pharmacogenomics and personalised drug treatment
    V. Annibali
    G. Ristori
    S. Cannoni
    S. Romano
    A. Visconti
    A. Ghazaryan
    L. Figà Talamanca
    M. Salvetti
    R. Mechelli
    Neurological Sciences, 2006, 27 : s347 - s349
  • [33] Immune parameters of patients treated with laquinimod, a novel oral therapy for the treatment of multiple sclerosis: results from a double-blind placebo-controlled study
    Stasiolek, Mariusz
    Linker, Ralf A.
    Hayardeny, Liat
    Bar Ilan, Oren
    Gold, Ralf
    IMMUNITY INFLAMMATION AND DISEASE, 2015, 3 (02): : 45 - 55
  • [34] Treatment of Multiple Sclerosis: A Review
    Hauser, Stephen L.
    Cree, Bruce A. C.
    AMERICAN JOURNAL OF MEDICINE, 2020, 133 (12) : 1380 - +
  • [35] Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis
    Lattanzi, Simona
    Cagnetti, Claudia
    Danni, Maura
    Provinciali, Leandro
    Silvestrini, Mauro
    JOURNAL OF NEUROLOGY, 2017, 264 (08) : 1697 - 1704
  • [36] Potential neuroprotective effect of Fingolimod in multiple sclerosis and its association with clinical variables
    Pitteri, Marco
    Magliozzi, Roberta
    Bajrami, Albulena
    Camera, Valentina
    Calabrese, Massimiliano
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (04) : 387 - 395
  • [37] The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
    Warrender-Sparkes, Matthew
    Spelman, Tim
    Izquierdo, Guillermo
    Trojano, Maria
    Lugaresi, Alessandra
    Grand'Maison, Francois
    Havrdova, Eva
    Horakova, Dana
    Boz, Cavit
    Oreja-Guevara, Celia
    Alroughani, Raed
    Iuliano, Gerardo
    Duquette, Pierre
    Girard, Marc
    Terzi, Murat
    Hupperts, Raymond
    Grammond, Pierre
    Petersen, Thor
    Fernandez-Bolanos, Ricardo
    Fiol, Marcela
    Pucci, Eugenio
    Lechner-Scott, Jeannette
    Verheul, Freek
    Cristiano, Edgardo
    Van Pesch, Vincent
    Petkovska-Boskova, Tatjana
    Moore, Fraser
    Kister, Ilya
    Bergamaschi, Roberto
    Laura Saladino, Maria
    Slee, Mark
    Barnett, Michael
    Amato, Maria Pia
    Shaw, Cameron
    Shuey, Neil
    Young, Carolyn
    Gray, Orla
    Kappos, Ludwig
    Butzkueven, Helmut
    Kalincik, Tomas
    Jokubaitis, Vilija
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (04) : 520 - 532
  • [38] Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
    Burton, Jodie M.
    O'Connor, Paul W.
    Hohol, Marika
    Beyene, Joseph
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2012, (12):
  • [39] Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis
    Moore, Spencer
    Khalaj, Anna J.
    Yoon, JaeHee
    Patel, Rhusheet
    Hannsun, Gemmy
    Yoo, Timothy
    Sasidhar, Manda
    Martinez-Torres, Leonardo
    Hayardeny, Liat
    Tiwari-Woodruff, Seema K.
    BRAIN AND BEHAVIOR, 2013, 3 (06): : 664 - 682
  • [40] From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis
    Aly, Lilian
    Hemmer, Bernhard
    Korn, Thomas
    CURRENT NEUROPHARMACOLOGY, 2017, 15 (06) : 874 - 891
12345